BRCA2 and cancer: Tumour sequencing of all coding exons of the BRCA1 and BRCA2 genes was carried out in 641 (41.3%) cases, including patients with ovarian (OC, 154, 24%), biliopancreatic (BPC, 135, 21.1%), breast (BC, 36, 5.6%) and prostate (PC, 12, 1.9%) cancer, as well as other tumours not typically associated with BRCA1/2 PVs, including gastrointestinal (GI) tumours (147, 22.9%) and other histotypes (157, 24.5%).